Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.

MLA

Czuczman, Natalie M., et al. “Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Is Active in Mantle Cell Lymphoma and Enhances Rituximab Activity in Vivo.” Blood, vol. 127, no. 9, Mar. 2016, pp. 1128–37. EBSCOhost, https://doi.org/10.1182/blood-2015-04-640920.

APA

Czuczman, N. M., Barth, M. J., Gu, J., Neppalli, V., Mavis, C., Frys, S. E., Hu, Q., Liu, S., Klener, P., Vockova, P., Czuczman, M. S., & Hernandez-Ilizaliturri, F. J. (2016). Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo. Blood, 127(9), 1128–1137. https://doi.org/10.1182/blood-2015-04-640920

Chicago

Czuczman, Natalie M, Matthew J Barth, Juan Gu, Vishala Neppalli, Cory Mavis, Sarah E Frys, Qiang Hu, et al. 2016. “Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Is Active in Mantle Cell Lymphoma and Enhances Rituximab Activity in Vivo.” Blood 127 (9): 1128–37. doi:10.1182/blood-2015-04-640920.